{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.701","upperLimit":"0.951","value":"0.876"},{"groupId":"OG001","lowerLimit":"0.701","upperLimit":"0.951","value":"0.876"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"title":"PET-CT positive"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"PET-CT negative"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"description":"Log-rank analysis will be used to investigate the prognostic value of FDG-PET scans at baseline, after 2 courses and post-therapy in patients with HIV and HL with respect to progression free survival.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.\n\nBrentuximab Vedotin: Given IV\n\nDacarbazine: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nPharmacological Study: Correlative studies\n\nVinblastine: Given IV","id":"OG000","title":"Phase I - Brentuximab 1.2 mg/kg"},{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.\n\nBrentuximab Vedotin: Given IV","id":"OG001","title":"Phase II - Brentuximab 1.2 m/kg"}],"paramType":"NUMBER","populationDescription":"PET-CT positive status was used within each arm.","reportingStatus":"POSTED","timeFrame":"Baseline up to 2 years","title":"Prognostic Value of Fludeoxyglucose F-18 (FDG)-Positron Emission Tomography (PET) in Patient With HIV and Hodgkin Lymphoma (HL) With Respect to 2 Year Progression Free Survival","type":"SECONDARY","unitOfMeasure":"proportion of participants"}